Profound gastric mucosal changes and severe rebound acid hypersecretion after long‐term Vonoprazan use: A case report
Abstract Vonoprazan is a novel acid blocker with greater potency than proton pump inhibitors. A Japanese study reported no significant safety concerns over 5 years of Vonoprazan use; however, elevated serum gastrin and increased parietal cell and foveolar hyperplasia were observed, and long‐term saf...
Saved in:
| Main Authors: | Hiroko Suda, Sachi Eto, Koichi Sakurai |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | DEN Open |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/deo2.70046 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review
by: Gerson Domingues, et al.
Published: (2022-08-01) -
Endoscopic findings and outcomes of gastric mucosal changes relating to potassium‐competitive acid blocker and proton pump inhibitor therapy
by: Satoshi Shinozaki, et al.
Published: (2025-04-01) -
Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review
by: Décio Chinzon, et al.
Published: (2021-12-01) -
The Effect of Esomeprazole 40 mg Single Therapy in Patients with Non-Erosive Reflux Disease Who Are Resistant to Standard-Dose Proton Pump Inhibitor Therapy: An Open-Label Multicenter Study
by: Jae Kyu Sung, et al.
Published: (2016-12-01) -
Gastroesophageal reflux disease, resistant to proton pump inhibitors
by: V. O. Kaybysheva, et al.
Published: (2011-06-01)